Simplifying PrEP: Is monitoring needed?
MODERATOR
Sheena McCormack
MRC Clinical Trials Unit at UCL, United Kingdom
Share
Current TDF-based PrEP programmes generally require regular monitoring for renal and bone health, with regular HIV and STI testing. This introduces complexity into the set-up and implementation of national PrEP programmes and, in some settings, has limited the number of people who are able to access PrEP. PrEP based on other drugs (such as LA CAB) may reduce the need for some aspects of this monitoring, but STI/HIV testing requirements are likely to remain. Following the COVID-19 pandemic, the population is more used to self-testing, and new technologies have opened opportunities for new approaches to self-care. This could pave the way for people receiving PrEP to take responsibility for their own monitoring and/or testing, reducing the impact on PrEP delivery systems. It remains unclear, however, whether this would be feasible or acceptable to those receiving PrEP and whether it could increase rather than decrease inequalities.
15:00
2 min
Introduction
MRC Clinical Trials Unit at UCL, United Kingdom
15:02
10 min
Why does PrEP have to be so complicated?
Wits RHI, South Africa
15:12
30 min
Panel discussion
Institute of HIV Research and Innovation, Thailand
PrEPster, United Kingdom
BC Centre for Excellence in HIV/AIDS, Canada
Beth Israel Deaconess Medical Center, United States
15:42
18 min
Q&A and conclusion
MRC Clinical Trials Unit at UCL, United Kingdom
Wits RHI, South Africa
Institute of HIV Research and Innovation, Thailand
PrEPster, United Kingdom
BC Centre for Excellence in HIV/AIDS, Canada
Beth Israel Deaconess Medical Center, United States
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT